News
-
Novartis bids farewell to popular leader
- Fri Oct 2
After 25 years in the industry including 10 at Novartis, one of the company’s strongest leaders and resident ‘Nice Guy’ is leaving, ready for a new chapter.
Read more -
Big earners face first PBS competitors
- Fri Oct 2
Celltrion’s ninth PBS biosimilar takes on Roche’s Actemra as Novartis’ TKI Tasigna also faces its first competitors on the PBS.
Read more -
Sandoz tops GPTW rankings for 2026
- Fri Oct 2
Great Place to Work reveals the Top 10 Biotech and Pharma Companies of 2026, Sandoz beating out four innovative companies to top the 2026 list.
Read more -
US Administration releases GLOBE framework
- Fri Oct 2
The Final Rule positions GLOBE as a narrower, more targeted mechanism than originally proposed but still embeds international reference pricing into US federal regulation.
Read more -
ANZ pharma’s reputation slips again
- Wed Sep 30
Despite a slight uptick last year, ANZ pharma’s reputation now hovers just above neutral, according to patient organisations, access and integrity pulling it down.
Read more -
Boehringer named ‘best in class’ by ANZ patients
- Wed Sep 30
For the second year in a row, Boehringer Ingelheim has been named by patient organisations as having the best reputation in ANZ. See who else ranked, and who’s improved.
Read more -
Horizon scanning moves forward; HTA reform left behind
- Wed Sep 30
Inaugural Health Innovation Observatory symposium shows horizon scanning progress as patients express concerns about HTA’s ability to deliver access.
Read more -
Gallagher pins budget windfall on PBS savings
- Wed Sep 30
Lower-than-expected spending on PBS named by Federal Finance Minister as one reason 2025-26 budget outcome was ‘better than expected’.
Read more